Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PYGM | P11217 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975333 | 1.00 | HDAC6 (0.47) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL1626018 | 0.89 | HDAC6 (0.37) | HDAC6CDK5CDK5R1HSPA8CCNA2 | |
| SCHEMBL9975424 | 0.89 | HDAC6 (0.37) | HDAC6CDK5CDK5R1HSPA8CCNA2 | |
| SCHEMBL9973810 | 0.88 | HDAC6 (0.47) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL9975366 | 0.85 | HDAC6 (0.45) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL9975364 | 0.85 | HDAC6 (0.48) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL1627706 | 0.85 | HDAC6 (0.45) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL1626310 | 0.85 | HDAC6 (0.48) | HDAC6CDK5CDK5R1HSPA8CDK1 | |
| SCHEMBL9975391 | 0.84 | SLC15A1 (0.41) | HDAC6CDK5CDK5R1HSPA8ALDH1A1 | |
| SCHEMBL12750767 | 0.84 | HDAC6 (0.44) | HDAC6CDK5CDK5R1HSPA8CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-25 | — | — | US | disclosed |
| US-8202844-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-21 | — | — | US | disclosed |
| US-7928080-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-04-19 | — | — | US | disclosed |
| US-7625871-B2 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-12 | — | — | US | disclosed |
| US-7419963-B2 | Indole antiviral compositions and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-02 | — | — | US | disclosed |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-06-19 | — | — | US | disclosed |
| US-20050143329-A1 | Indole antiviral compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281052-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK5 76/4885CDK5R1 137/4885 |
| US-20120270827-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK5 76/4885CDK5R1 137/4885 |
| US-20080146517-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK5 76/4885CDK5R1 137/4885 |
| US-20050143329-A1 | Indole antiviral compositions and methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK5 76/4885CDK5R1 137/4885 |
| US-20110178038-A1 | Indole Antiviral Compositions And Methods | IDO1, IDO2, MAVS | HDAC6 536/4885CDK5 76/4885CDK5R1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.